Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, Ruijun Zhang et al.|Science|2015Cited by 202
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)Gavin Churchyard, Cecilia Morgan, Elizabeth M. Adams et al.|PLoS ONE|2011Cited by 137
Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or ImmunizationCheng Cheng, Gary J. Nabel, Jason G. Gall et al.|Journal of Virology|2009Cited by 75
Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical TrialBeryl A. Koblin, Martín Casapía, Cecilia Morgan et al.|PLoS ONE|2011Cited by 43
Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative SubjectsLindsey R. Baden, William A. Blattner, Cecilia Morgan et al.|The Journal of Infectious Diseases|2011Cited by 25